Edinburgh Cell Analysis Startup, Cytomos, Secures £4 Million in Funding Round Led by Archangels

EDINBURGH — Cytomos, an innovative cell analysis startup based in Edinburgh, has successfully raised a substantial £4 million in a recent funding round, with the prominent Scottish angel network, Archangels, at the helm. This strategic infusion of capital is poised to propel the company’s pioneering dielectric spectroscopy technology to new heights, with the overarching goal of expediting the introduction of therapeutic solutions to market.

The applications of Cytomos’ cutting-edge technology are far-reaching, encompassing critical domains such as drug development, gene therapy manufacturing, and bioprocessing. Bolstered by this funding, Cytomos is steadfastly committed to actualizing its vision of commercializing its advanced cell platform within the coming year, while also fortifying its talented workforce.

This milestone achievement comes hot on the heels of a series of strategic leadership appointments undertaken by Cytomos in October, a prudent measure taken in anticipation of the forthcoming Series A funding round, headquarters relocation, and the fine-tuning of its pioneering product. As elucidated by Sarah Hardy, the Director and Head of New Investments at Archangels, Cytomos’ lofty aspiration to elevate real-time cell analysis methods, tailored to the discerning needs of end users, has the potential to catalyze a paradigm shift in the development and market introduction of products within the realms of bioprocessing and cell and gene therapies.

Prominent players in the investment landscape, such as Old College Capital, Scottish Enterprise, and the British Business Bank, have also recognized the immense promise harbored by Cytomos, as evidenced by their participation in this transformative funding round. The burgeoning startup, under the stewardship of its Chief Executive, David Rigterink, is poised to harness the synergy between consumer electronics technology and the intricate demands of the bioprocess industry, thereby carving a unique niche in the market.

Notably, Cytomos had previously secured a commendable £1.6 million in seed funding for its revolutionary cell platform in June of the preceding year. Adding to its accolades, Archangels recently solidified its commitment to fostering innovation by entering into a co-investment agreement with British Business Investments, a partnership bearing a substantial value of £12 million.

Cytomos’ commendable strides and the substantial investment it has garnered collectively underscore its pivotal role as a catalyst in reshaping the landscape of cell analysis and bioprocessing. As the company surges forward, fueled by its visionary technology and formidable financial backing, it holds the potential to redefine the trajectory of therapeutic advancements and scientific progress.”